The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
Explore this paper's citation graph
Summary
In a xenograft model of lymphoma, human T cells expressing humanized scFvs exhibited the same anti-tumor efficacy as those expressing murine scFv and prolonged survival compared with cells expressing control CAR.
- Type
- article
- Published
- 2016-06-01
- Cited by
- 31
- References
- 17
- OpenAlex
- https://openalex.org/W2298570758
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2377962
Keywords
Chimeric antigen receptor, Single-chain variable fragment, Humanized mouse, CD19, Antigen
References
- Engineering CAR-T Cells: Design Concepts
- Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
- IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
- The use of endogenous T cells for adoptive transfer
- Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells
- Improving treatment strategies for acute lymphoblastic leukemia by combining immunotherapy and chemotherapy.
- CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
- Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
- OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
- Engineering T cells for cancer: our synthetic future
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- Adoptive T Cell Therapy for Cancer: Boutique Therapy or Treatment Modality?
- Chimeric Antigen Receptor–Modified T Cells in CLL
Cited by
- Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia
- The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells
- Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
- Genetically enhanced T lymphocytes and the intensive care unit
- Potent anti‐leukemia activities of humanized CD19‐targeted Chimeric antigen receptor T (CAR‐T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
- CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
- Traitement par CAR-T des leucémies aiguës de l'adulte
- Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.
- 3D Nanochannel Electroporation for Macromolecular Nucleotide Delivery.
- CAR T cell therapy: A new era for cancer treatment (Review).
- Chimeric antigen receptor T‐cell therapies: Optimising the dose
- Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
- New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry
- 造血干细胞移植后复发急性B淋巴细胞白血病CD19 CAR-T细胞治疗后的维持治疗
- CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity
- Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
- In like a lamb; out like a lion: Marching CAR T cells towards enhanced efficacy in B-ALL
- The antigen‐binding moiety in the driver's seat of CARs
- A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
- Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
Related papers
- 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- Distribution Measurements of Chimeric Antigen Receptor-Modified T Cells Against CD19
- B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?
- Anti-cd19-car-transduced-t-cells/chimeric-antigen-receptor-t-cell-therapeutics-shanghai-unicar-therapy-bio-medicine-technology
- Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy.
- Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions
- Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
- Comparison of three humanized mouse models for adoptive T cell transfer
- Validation of Pre-Treatment Modified Easix Score As a Predictor of Cytokine Release Syndrome Related to Anti CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)